Innovative Therapies Days 2024

9–12 Oct 2024 | BESANCON, France

Advesya

advesya.comParis, France
1 profile visit

About

Established by founders Christophe Ferrand and Marina Deschamps, Advesya is a spin-out from the French Blood Institute (EFS) in Besançon (France), where it is deeply integrated into the medical and research community. Fueled by experts in drug development (spanning from target validation to product launch) since it was seeded by Jeito in 2022, the company is on a mission to deliver innovative treatment options to patients with critical unmet medical needs. Advesya has quickly evolved into a clinical-stage company and is now developing novel and customized treatment modalities, including a CAR T-cell (CCTx-001) and an ADC (ADV-101) that are tailored to each disease associated with IL-1RAP dysregulation.

Representatives

Jens Hasskarl

chief medical officer

Advesya